Myrcludex B: Phase IIb started

The companies began the open-label, Russian Phase IIb MYR 203 trial to compare Myrcludex B plus pegylated interferon alpha vs. pegylated interferon alpha alone in 60 patients. Hepatera in-licensed rig...